Wedbush Issues Positive Forecast for Arvinas Earnings

Arvinas, Inc. (NASDAQ:ARVN) – Equities research analysts at Wedbush increased their Q3 2025 earnings estimates for Arvinas in a note issued to investors on Wednesday, August 6th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.60) for the quarter, up from their previous forecast of ($0.76). The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas’ Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($1.99) EPS, FY2027 earnings at ($3.55) EPS, FY2028 earnings at ($2.76) EPS and FY2029 earnings at ($2.40) EPS.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.03. The business had revenue of $22.40 million during the quarter, compared to analyst estimates of $34.42 million. Arvinas had a negative net margin of 19.47% and a negative return on equity of 12.01%. Arvinas’s quarterly revenue was down 70.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.49) earnings per share.

Several other equities research analysts have also issued reports on the stock. Leerink Partnrs lowered shares of Arvinas from a “strong-buy” rating to a “hold” rating in a report on Sunday, June 1st. Morgan Stanley lowered their target price on shares of Arvinas from $12.00 to $11.00 and set an “equal weight” rating for the company in a report on Friday, May 9th. Wells Fargo & Company lowered their target price on shares of Arvinas from $19.00 to $16.00 and set an “overweight” rating for the company in a report on Thursday. Jefferies Financial Group restated a “hold” rating and issued a $10.00 target price (down previously from $52.00) on shares of Arvinas in a report on Friday, May 2nd. Finally, Barclays reduced their price target on shares of Arvinas from $32.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $19.76.

Arvinas Trading Up 0.8%

Arvinas stock opened at $6.29 on Monday. The firm has a 50-day moving average price of $7.52 and a 200-day moving average price of $9.86. The firm has a market capitalization of $461.81 million, a PE ratio of -6.23 and a beta of 2.22. Arvinas has a 12-month low of $5.90 and a 12-month high of $29.61.

Institutional Trading of Arvinas

A number of institutional investors have recently bought and sold shares of ARVN. GF Fund Management CO. LTD. acquired a new stake in Arvinas in the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd boosted its stake in Arvinas by 965.4% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company’s stock worth $33,000 after purchasing an additional 4,219 shares in the last quarter. CWM LLC boosted its stake in Arvinas by 2,317.5% in the 1st quarter. CWM LLC now owns 7,615 shares of the company’s stock worth $53,000 after purchasing an additional 7,300 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Arvinas in the 2nd quarter worth approximately $74,000. Finally, Aigen Investment Management LP acquired a new stake in Arvinas in the 1st quarter worth approximately $77,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Arvinas

In other news, CFO Andrew Saik sold 5,700 shares of the firm’s stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total value of $43,377.00. Following the sale, the chief financial officer directly owned 164,401 shares in the company, valued at approximately $1,251,091.61. This trade represents a 3.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.73% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.